|
|
|
|
|
Highlights from the 36th Annual EAU Virtual Congress |
|
|
|
|
|
| First Results of PEACE-1 A Phase 3 Trial with a 2x2 Factorial Design of Abiraterone Acetate plus Prednisone and/or Local Radiotherapy in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer mCSPC |
| Karim Fizazi, MD, Ph.D. |
| Karim Fizazi joins Alicia Morgans discussing first results of the PEACE-1 trial presented earlier this year at ASCO 2021. Dr. Fizazi also shares with Dr. Morgans that the addition of abiraterone acetate to the standard of care including ADT and docetaxel significantly improves rPFS in men with de novo mCSPC without meaningful differences in short-term toxicity. However, overall survival data are immature. |
|
|
|
|
|
|
|
|
|
| Detailed Analysis of Radiographic Progression-Free Survival in the PEACE-1 Phase 3 Trial
|
| Karim Fizazi, MD, Ph.D.
|
| Karim Fizazi presents the results of the PEACE-1 randomized phase 3 clinical trial with a focus on the impact of adding abiraterone acetate + prednisone to ADT+docetaxel on radiographic progression-free survival (rPFS) during this session at the 2021 European Association of Urology, (EAU) annual meeting. The results of the PEACE-1 randomized phase 3 clinical trial were previously presented at ASCO 2021.
|
|
|
|
|
|
| PEACE-1 Phase 3 Clinical Trial Discussion - Important Considerations For Its Interpretation
|
| Axel Heidenreich, Prof. Dr. med.
|
| Following the presentation by Dr. Karim Fizazi on the phase 3 PEACE-1 trial. Dr. Axel Heidenreich provides a discussion presentation on important considerations for interpretation of this trial. The PEACE-1 phase 3 trial studied abiraterone acetate plus prednisone added to androgen deprivation therapy and docetaxel in men with de novo metastatic castration-sensitive prostate cancer (mCSPC).
|
|
|
|
|
|
| Lymphadenectomy for Prostate Cancer: When and How?
|
| Axel Heidenreich, Prof. Dr. med. |
| Axel Heidenreich discussed when and how to perform lymphadenectomy for prostate cancer at the joint session of the EAU and the Confederacion Americana De Urologica. Dr. Heidenreich notes that the rationale of pelvic lymphadenectomy is to (i) identify micrometastatic spread to locoregional lymph nodes, (ii) assess risk of future progression, (iii) decide on the best individual approach for the patient (ie. surveillance versus adjuvant therapy), and (iv) improve oncological outcome in terms of progression and survival.
|
|
|
|
|
|
| Surgical Treatment of Lymph Node Recurrences After Radical Prostatectomy - Pro Surgery |
| Nicola Fossati, MD |
| The joint session of the European Association of Urology EAU and the Confederacion Americana de Urologia included a session discussing the surgical treatment of lymph node recurrences after radical prostatectomy. Dr. Nicola Fossati from San Raffaele, Milan took the pro surgery approach for his presentation. |
|
|
|
|
|
| Surgical Treatment of Lymph Node Recurrences After Radical Prostatectomy - Pro Radiotherapy |
| Piet Ost, MD, Ph.D. |
| The joint session of the European Association of Urology and the Confederacion Americana de Urologia included a session discussing the surgical treatment of lymph node recurrences after radical prostatectomy. Piet Ost took the pro radiotherapy approach for his presentation. |
|
|
|
|
|
| Is Nuclear Medicine Taking Over the Treatment of Metastatic Prostate Cancer? PRLT Is Only a Tessera in the Treatment of CRPC
|
| Frederic Pouliot, MD, Ph.D., FRCSC
|
| In this presentation, Frederic Pouliot suggests that prostate radioligand therapy is only a tessera in the treatment of CRPC. Dr. Pouliot notes that theranostics is the combination of imaging and therapy, most commonly 177Lu-PSMA radioligand therapy. Radioligand therapy is promising, but Dr. Pouliot poses: is it really as simple as PSMA PET positive disease = PSMA radioligand targetable = PSA response = clinical benefits?
|
|
|
|
|
|
| Is Nuclear Medicine Taking Over the Treatment of Metastatic Prostate Cancer? PRLT Could Do Much More If Applied Earlier and Repetitive
|
| Christian La Fougere, MD
|
| The European Association of Urology (EAU) 2021 Virtual Annual Meeting included a joint session of the EAU and the Canadian Urological Association and a presentation by Christian La Fougere discussing prostate radioligand therapy and its use earlier in the disease process.
|
|
|
|
|
|
| The Role of Adjuvant Radiotherapy Following Radical Prostatectomy in Men with High Risk Disease
|
| Peter Bostrom, MD, Ph.D.
|
| Peter Bostrom discusses the role of adjuvant radiotherapy following radical prostatectomy in men with high-risk disease. Dr. Bostrom notes that there are several risk factors that must be taken into account when assessing a patient’s risk for biochemical recurrence/consideration for adjuvant radiotherapy. He touches on several open questions that remain to be answered, and provides take-home considerations in this space.
|
|
|
|
|
|
|
|
|
|
|
| PSA, Imaging and Beyond: Make Indications for Biopsy as PRECISE as Possible |
| Antonio Finelli, MD |
| Antonio Finelli discusses the importance of making indications for prostate biopsy as precise as possible. Dr. Finelli notes that the question of who and how we should biopsy men is a difficult question to address. Ultimately, the takeaway from all of these additional tests and indicators is the shared decision-making process. The threshold for biopsy varies for each man and the biopsy decision must incorporate patient preferences and personal risk tolerance. |
|
|
|
|
|
| PSA, Imaging and Beyond: Keep it Simple |
| Nicolas Mottet, MD, Ph.D. |
| The joint session of the European Association of Urology (EAU) and the Canadian Urological Association at the 2021 EAU annual meeting included a discussion on PSA, Imaging and Beyond for assessing men for prostate biopsy and a presentation by Dr. Nicolas Mottet about keeping the process simple. Dr. Mottet notes that an indication for biopsy should be reserved for when a diagnosis is needed, in an asymptomatic man with an abnormal DRE or elevated PSA, and occasionally in symptomatic men (if the symptoms are possibly related to prostate cancer). |
|
|
|
|
|
| Can Prostate Cancer Follow-up Databases Safely Reduce Clinic Numbers |
| Stephen Mark, MD |
| Stephen Mark discusses aspects of a prostate cancer follow-up database to safely reduce patient clinic visits. Dr. Mark notes that there is generally a wide variation in prostate cancer follow-up, with options for follow-up including in-person clinic visits, telehealth, general practitioner (60% compliance) visits, patient e-portals, and no formal follow-up. |
|
|
|
|
|
| Prostate Cancer in 2020 and Beyond: Re-Imagining Survivorship
|
| Suzanne Chambers, AO
|
| In this presentation, Suzanne Chambers discusses prostate cancer survivorship. Dr. Chambers highlights that men with prostate cancer should be regularly screened for psychological distress, given that not an insignificant number of prostate cancer survivors will have depression, distress, and even suicidal ideation.
|
|
|
|
|
|
|
|
| To view our full coverage of the 2021 EAU Virtual Congress, visit the Conference Coverage section on UroToday.com |
|
|
|
|
|
|
 |
|
|
|
|
